CAJ | 학술논문

目的观察阿托伐他汀对脑外伤后小鼠血脑屏障的影响,探讨阿托伐他汀在脑外伤治疗中的作用.方法将120只C57/BL6小鼠随机分为假手术组、生理盐水组和阿托伐他汀组,各40只.生理盐水组和阿托伐他汀组采用液压打击法制作脑外伤模型.假手术组不进行液压打击.阿托伐他汀组打击后1h予阿托伐他汀(每天1 mg/kg)灌胃,连续14 d.生理盐水组予等量生理盐水灌胃.造模后第1、3、7、14天对各组小鼠神经功能进行改良神经功能缺损评分(mNSS);第1、3、7天干湿比重法检测脑组织水含量、Evans Blue法检测血脑屏障渗漏、免疫组织化学检测基质金属蛋白酶-9(MMP-9)水平;第3天Western blot检测紧密连接蛋白-5(Claudin-5)水平.结果阿托伐他汀组小鼠第7、14天mNSS评分(分)明显低于生理盐水组(6.33±0.71比8.33±0.70、3.44±0.73比6.11 ±0.60,P＜0.05).造模后第3天,阿托伐他汀组小鼠脑组织含水量[(80.06±0.15)％比(82.10±0.26)％]、Evans Blue(2.23±0.06比2.57 ±0.05)、Claudin-5检测值(0.61±0.01比0.29±0.01)与生理盐水组比较差异有统计学意义(P＜0.05).造模后第3、7天阿托伐他汀组小鼠MMP-9阳性表达量与生理盐水组小鼠MMP-9阳性表达量比较显著降低(220.16±9.70比311.67 ±5.99、203.00±4.94比288.83±8.52,P＜0.05).结论阿托伐他汀能改善脑外伤小鼠神经功能,可能与阿托伐他汀对血脑屏障的影响相关.
목적 관찰아탁벌타정대뇌외상후소서혈뇌병장적영향,탐토아탁벌타정재뇌외상치료중적작용.방법 장120지C57/BL6소서수궤분위가수술조、생리염수조화아탁벌타정조,각40지.생리염수조화아탁벌타정조채용액압타격법제작뇌외상모형.가수술조불진행액압타격.아탁벌타정조타격후1h여아탁벌타정(매천1 mg/kg)관위,련속14 d.생리염수조여등량생리염수관위.조모후제1、3、7、14천대각조소서신경공능진행개량신경공능결손평분(mNSS);제1、3、7천간습비중법검측뇌조직수함량、Evans Blue법검측혈뇌병장삼루、면역조직화학검측기질금속단백매-9(MMP-9)수평;제3천Western blot검측긴밀련접단백-5(Claudin-5)수평.결과 아탁벌타정조소서제7、14천mNSS평분(분)명현저우생리염수조(6.33±0.71비8.33±0.70、3.44±0.73비6.11 ±0.60,P＜0.05).조모후제3천,아탁벌타정조소서뇌조직함수량[(80.06±0.15)％비(82.10±0.26)％]、Evans Blue(2.23±0.06비2.57 ±0.05)、Claudin-5검측치(0.61±0.01비0.29±0.01)여생리염수조비교차이유통계학의의(P＜0.05).조모후제3、7천아탁벌타정조소서MMP-9양성표체량여생리염수조소서MMP-9양성표체량비교현저강저(220.16±9.70비311.67 ±5.99、203.00±4.94비288.83±8.52,P＜0.05).결론 아탁벌타정능개선뇌외상소서신경공능,가능여아탁벌타정대혈뇌병장적영향상관.
Objective 一o observe the effect of atorvastatin administration on the blood-brain barrier of traumatic brain injury (TBI) mice,and study the role of atorvastatin in the treatment of TBI.Methods 120 adult male C57/BL6 mice were randomly divided into the sham group,atorvastatin group and saline group,40 each.The atorvastatin group and saline group were given hydraulic combat to establish TBI models.The sham group mice underwent the same surgical procedure without being exposed to percussion injury.The atorvastatin group mice were treated with atorvastatin (orally,1 mg/kg) 1 h after TBI and then daily for 14 consecutive days.The saline group mice were given saline orally.The modified neurological severity scores (mNSS) test was conducted at 1st,3rd,7th and 14th day after TBI.Brain edema was measured at 1st,3rd,and 7th day after TBI.The leakage of blood-brain barrier was detected by Evans Blue method at 1st,3rd,and 7th day after TBI.The expression of matrix metalloproteinase-9 (MMP-9) was detected by immunohistochemical staining at 1 st,3rd,and 7th day after TBI,and that of Claudin-5 by Western blotting at 3rd day after TBI.Results The mNSS was statistically significant between atorvastatin group and saline group at 7th,and 14th day after TBI (6.33 ±0.71 vs.8.33 ±0.70,and 3.44 ±0.73 vs.6.11 ± 0.60,P＜0.05).The content of water [(80.06±0.15)％ vs.(82.10±0.26)％],evans blue (EB,2.23 ±0.06 vs.2.57 ±0.05) and Claudin-5 (0.61 ±0.01 vs.0.29 ±0.01) showed statistically significant difference between atorvastatin group and saline group at 3rd day after TBI (P ＜ 0.05).The MMP-9 was statistically significant between atorvastatin group and saline group at 3rd,and 7th day after TBI (220.16 ± 9.70 vs.311.67 ± 5.99,and 203.00 ± 4.94 vs.288.83 ± 8.52,P ＜ 0.05).Conclusion Atorvastatin may improve neural function of TBI mice by influencing the blood-brain barrier.